• 5 WEST 2.18

Accepting PhD Students

20082019
If you made any changes in Pure these will be visible here soon.

Personal profile

Willing to supervise PhD

and PostDocs

I welcome motivated PhD students and PostDocs with a biological science background who are interested in cancer biology and drug discovery. If you would like to apply for a scholarship to join my lab please contact me well in advance.

Research interests

My research group is working at the interface of basic and translational cancer research.

I am interested in the metastatic tumour niche, particularly of breast cancer, and the interaction of tumour cells with the microenvironment, such as fibroblasts and immune cells. By combining metastasis models with in vitro 2D and 3D co-culture models, live cell- and high content imaging, we aim to identify novel strategies to target the tumour and/or stroma for the prevention or suppression of metastatic cancer and to overcome treatment-resistant tumour progression.

 

Metastatic Cancer

The majority of cancer-related deaths are due to metastatic disease and only 15% of stage IV breast cancer patients survive more than 5 years. Despite advances in identifying major drivers of primary tumour growth and the development of novel targeted therapies, there remains an unmet clinical need to develop treatment strategies targeting metastatic disease and intrinsic and acquired resistance. It is now well established that successful tumour progression involves a close crosstalk between tumour cells and the stromal microenvironment, including fibroblasts, pericytes, endothelial and immune cells but also the extracellular matrix (ECM). Furthermore, there is growing evidence that the stroma can modulate therapy resistance.

 

Biography

I hold a master’s degree (Magistra rerum naturalium) in Chemistry from the University Vienna and in Toxicology (MScTox) from the Medical University Vienna. I carried out my PhD at the Institute of Cancer Research at the Medical University Vienna in the group of Walter Berger. As a member of the inter-university cluster project for Translational Cancer Therapy Research, we investigated novel metal-based anticancer drugs, including oxaliplatin derivatives and gallium- and ruthenium drugs.

I then was awarded a Schrödinger Postdoctoral Fellowship from the Austrian Science Fund to join the group of Clare Isacke at the Institute of Cancer Research ICR London. My research focused on the metastasis-promoting role of cancer-associated fibroblasts. Furthermore, I developed a syngeneic, spontaneously metastasising breast cancer in vivo model.

In 2018, I established my own research lab in the Department of Pharmacy & Pharmacology at the University of Bath. I am a member of the Centre of Therapeutic Innovations CTI and in the committee of the Cancer Research at Bath CR@B network at the University.

Education/Academic qualification

Malignant Diseases, Doctor of Philosophy, Medical University of Vienna

Toxicology, Master of Science, Medical University of Vienna

Chemistry, Master of Chemistry, University of Vienna

Fingerprint Dive into the research topics where Ute Jungwirth is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 1 Similar Profiles
oxaliplatin Medicine & Life Sciences
Tumors Chemical Compounds
Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
Cytotoxicity Chemical Compounds
lapachol Chemical Compounds
Ruthenium Medicine & Life Sciences
Ruthenium Compounds Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2018

Extracellular matrix remodelling in breast cancer metastasis

Jungwirth, U.

1/06/1331/05/15

Project: Project at a former HEI

Research Output 2008 2019

Inhibition of stromal collagen receptor impairs breast cancer metastasis

Jungwirth, U., 3 Jul 2019.

Research output: Contribution to conferencePoster

Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation

van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U. & Isacke, C. M., 20 Jun 2019, In : Nature Communications. 10, 1, 2698.

Research output: Contribution to journalArticle

Open Access

Generation and characterisation of two D2A1 mammary cancer sublines to model spontaneous and experimental metastasis in a syngeneic BALB/c host

Jungwirth, U., van Weverwijk, A., Melake, M. J., Chambers, A. F., Gao, Q., Fivaz, M. & Isacke, C. M., 18 Jan 2018, In : Disease Models & Mechanisms. 11, 1, dmm031740.

Research output: Contribution to journalArticle

Open Access
Tumors
Assays
Theoretical Models
Cells
Breast Neoplasms

Inhibition of fibroblasts decreases metastatic breast cancer

Jungwirth, U., 12 Sep 2018.

Research output: Contribution to conferencePoster

12 Citations (Scopus)

Comparative studies of oxaliplatin-based platinum(iv) complexes in different in vitro and in vivo tumor models

Göschl, S., Schreiber-Brynzak, E., Pichler, V., Cseh, K., Heffeter, P., Jungwirth, U., Jakupec, M. A., Berger, W. & Keppler, B. K., 22 Mar 2017, In : Metallomics. 9, 3, p. 309-322 14 p.

Research output: Contribution to journalArticle

Open Access
oxaliplatin
Platinum
Tumors
Flow cytometry
Reducing Agents